Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin

Abstract

A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

What is claimed is: 
     
       1. A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component of a  Botulinum  toxin type B to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons. 
     
     
       2. The method of  claim 1 , wherein between about 100 units and about 1000 units of the neurotoxic component is administered. 
     
     
       3. The method of  claim 1 , wherein alleviation of the cervical dystonia occurs in about 3 to about 7 days. 
     
     
       4. A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component from a single  Botulinum  toxin type to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons, and wherein said  Botulinum  toxin is  Botulinum  toxin type B. 
     
     
       5. A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component from only a  Botulinum  toxin type B to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons. 
     
     
       6. The method of  claim 1 , wherein between about 80 units and about 460 units of the neurotoxic component is administered. 
     
     
       7. The method of  claim 1 , wherein the neurotoxic component is administered by intramuscular injection. 
     
     
       8. The method of  claim 1 , wherein an alleviation of a symptom of the cervical dystonia is evident 3 to 7 days after the administration of the neurotoxic component. 
     
     
       9. The method of  claim 4 , wherein between about 100 units and about 1000 units of the neurotoxic component is administered. 
     
     
       10. The method of  claim 4 , wherein between about 80 units and about 460 units of the neurotoxic component is administered. 
     
     
       11. The method of  claim 4 , wherein the neurotoxic component is administered by intramuscular injection. 
     
     
       12. The method of  claim 4 , wherein alleviation of the cervical dystonia occurs in about 3 to about 7 days. 
     
     
       13. The method of  claim 4 , wherein an alleviation of a symptom of the cervical dystonia is evident 3 to 7 days after the administration of the neurotoxic component. 
     
     
       14. The method of  claim 5 , wherein between about 100 units and about 1000 units of the neurotoxic component is administered. 
     
     
       15. The method of  claim 5 , wherein between about 80 units and about 460 units of the neurotoxic component is administered. 
     
     
       16. The method of  claim 5 , wherein the neurotoxic component is administered by intramuscular injection. 
     
     
       17. The method of  claim 5 , wherein alleviation of the cervical dystonia occurs in about 3 to about 7 days. 
     
     
       18. The method of  claim 5 , wherein an alleviation of a symptom of the cervical dystonia is evident 3 to 7 days after the administration of the neurotoxic component. 
     
     
       19. A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of a neurotoxic component of a  Botulinum  toxin type B, thereby reducing the severity of an abnormal head position symptom of cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons. 
     
     
       20. The method of  claim 19 , wherein between about 100 units and about 1000 units of the neurotoxic component is administered. 
     
     
       21. The method of  claim 19 , wherein between about 80 units and about 460 units of the neurotoxic component is administered. 
     
     
       22. The method of  claim 19 , wherein the neurotoxic component is administered by intramuscular injection. 
     
     
       23. The method of  claim 19 , wherein said severity is reduced in about 3 to about 7 days. 
     
     
       24. The method of  claim 19 , wherein reduction in said severity is evident 3 to 7 days after the administration of the neurotoxic component. 
     
     
       25. A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of a neurotoxic component of a  Botulinum  toxin type B, thereby reducing a neck pain symptom of cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons. 
     
     
       26. The method of  claim 25 , wherein between about 100 units and about 1000 units of the neurotoxic component is administered. 
     
     
       27. The method of  claim 25 , wherein between about 80 units and about 460 units of the neurotoxic component is administered. 
     
     
       28. The method of  claim 25 , wherein the neurotoxic component is administered by intramuscular injection. 
     
     
       29. The method of  claim 25 , wherein said symptom is reduced in about 3 to about 7 days. 
     
     
       30. The method of  claim 25 , wherein reduction in said symptom is evident 3 to 7 days after the administration of the neurotoxic component.